MedinCell S.A. (MEDCL.PA)
EUR 16.8
(5.53%)
EUR 16.8
(5.53%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 9.16 Million EUR | -8.67% |
| 2022 | 9.88 Million EUR | 141.78% |
| 2021 | 4.09 Million EUR | -50.04% |
| 2020 | 8.18 Million EUR | 187.03% |
| 2019 | 2.85 Million EUR | 97.64% |
| 2018 | 1.44 Million EUR | -77.59% |
| 2017 | 6.43 Million EUR | -24.55% |
| 2016 | 8.53 Million EUR | 3.66% |
| 2015 | 8.23 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 FY | 9.03 Million EUR | -8.67% |
| 2023 Q2 | 6.98 Million EUR | 0.0% |
| 2023 Q4 | 3.76 Million EUR | 0.0% |
| 2022 Q2 | 6.02 Million EUR | 0.0% |
| 2022 Q4 | 3.86 Million EUR | 0.0% |
| 2022 FY | 9.88 Million EUR | 141.78% |
| 2021 Q2 | 1.6 Million EUR | 0.0% |
| 2021 Q4 | 2.48 Million EUR | 0.0% |
| 2021 FY | 4.09 Million EUR | -50.04% |
| 2020 FY | 8.18 Million EUR | 187.03% |
| 2020 Q4 | 6.96 Million EUR | 0.0% |
| 2020 Q2 | 1.22 Million EUR | 0.0% |
| 2019 Q4 | 895 Thousand EUR | 0.0% |
| 2019 FY | 2.85 Million EUR | 97.64% |
| 2019 Q2 | 1.95 Million EUR | 0.0% |
| 2018 Q4 | 2.24 Million EUR | 100.0% |
| 2018 Q3 | 1.12 Million EUR | -37.65% |
| 2018 Q1 | 900.5 Thousand EUR | -83.9% |
| 2018 Q2 | 1.8 Million EUR | 100.0% |
| 2018 FY | 1.44 Million EUR | -77.59% |
| 2017 Q2 | 2.7 Million EUR | 100.0% |
| 2017 Q4 | 5.59 Million EUR | 100.0% |
| 2017 FY | 6.43 Million EUR | -24.55% |
| 2017 Q3 | 2.79 Million EUR | 3.27% |
| 2017 Q1 | 1.35 Million EUR | 0.0% |
| 2016 FY | 8.53 Million EUR | 3.66% |
| 2015 FY | 8.23 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | -97.414% |
| ABIVAX Société Anonyme | 4.62 Million EUR | -98.225% |
| Adocia SA | 2.15 Million EUR | -326.047% |
| Aelis Farma SA | 9.05 Million EUR | -1.171% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | -190.701% |
| genOway Société anonyme | 20.04 Million EUR | 54.306% |
| IntegraGen SA | 12.53 Million EUR | 26.939% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -2952.987% |
| Neovacs S.A. | 533.41 Thousand EUR | -1617.247% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | -444.747% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -46171.974% |
| Sensorion SA | 4.74 Million EUR | -93.124% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -2991.138% |
| TME Pharma N.V. | 17 Thousand EUR | -53782.353% |
| Valbiotis SA | 4.73 Million EUR | -93.535% |
| TheraVet SA | 1.07 Million EUR | -749.678% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | -408.889% |
| argenx SE | 1.13 Billion EUR | 99.192% |
| BioSenic S.A. | 543 Thousand EUR | -1586.924% |
| Celyad Oncology SA | 102 Thousand EUR | -8880.392% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 96.179% |
| Genfit S.A. | 28.56 Million EUR | 67.933% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | -338.908% |
| Innate Pharma S.A. | 51.9 Million EUR | 82.351% |
| Inventiva S.A. | 17.47 Million EUR | 47.588% |
| MaaT Pharma SA | 2.22 Million EUR | -311.131% |
| Nanobiotix S.A. | 30.05 Million EUR | 69.526% |
| Onward Medical N.V. | 532 Thousand EUR | -1621.805% |
| Oryzon Genomics S.A. | 14.19 Million EUR | 35.455% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -311.316% |
| Oxurion NV | 263 Thousand EUR | -3382.89% |
| Pharming Group N.V. | 245.31 Million EUR | 96.266% |
| Poxel S.A. | 1.98 Million EUR | -362.393% |
| GenSight Biologics S.A. | 1.26 Million EUR | -622.968% |
| Transgene SA | 1.18 Million EUR | -673.649% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.826% |
| Valneva SE | 153.71 Million EUR | 94.041% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 353.039% |